Monday, August 11, 1997
Emerging Company Profile
In 1996, the 6,000 genes in the yeast genome (Saccharomyces cerevisiae) were sequenced. The majority of these genes have human counterparts, and the majority of metabolic and signaling pathways are directly or indirectly coupled to similar genetic machinery in both human and yeast systems.
Acacia Biosciences is using its yeast-based Genome Reporter Matrix (GRM) technology to identify new drug targets, determine which compounds in a library have the greatest therapeutic index, identify potential side effects of a drug candidate and even resurrect failed drug candidates. GRM uses genetic response and chemical response profiles to evaluate a compound's effects over multiple disease pathways.